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The m-opioid receptor (OPRM1) is the principal receptor target for both endogenous and exogenous opioid
analgesics. There are substantial individual differences in human responses to painful stimuli and to opiate
drugs that are attributed to genetic variations in OPRM1. In searching for new functional variants, we employed
comparative genome analysis and obtained evidence for the existence of an expanded human OPRM1 gene
locus with new promoters, alternative exons and regulatory elements. Examination of polymorphisms within
the human OPRM1 gene locus identified strong association between single nucleotide polymorphism (SNP)
rs563649 and individual variations in pain perception. SNP rs563649 is located within a structurally conserved
internal ribosome entry site (IRES) in the 50-UTR of a novel exon 13-containing OPRM1 isoforms (MOR-1K) and
affects both mRNA levels and translation efficiency of these variants. Furthermore, rs563649 exhibits very
strong linkage disequilibrium throughout the entire OPRM1 gene locus and thus affects the functional contri-
bution of the corresponding haplotype that includes other functional OPRM1 SNPs. Our results provide
evidence for an essential role for MOR-1K isoforms in nociceptive signaling and suggest that genetic variations
in alternative OPRM1 isoforms may contribute to individual differences in opiate responses.
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INTRODUCTION
Opioid analgesics are the most widely used drugs to treat
moderate to severe pain, yet in addition to profound analgesia,
these agents also produce significant side-effects consisting of
miosis, sedation, nausea and vomiting, cognitive impairment,
constipation, rapid-onset hypotension and on occasion life-
threatening respiratory depression (1–4). There is consider-
able inter-individual variability in the clinical response to
opioid analgesics (5,6). For example, the minimal effective
analgesic concentration for opioids, such as morphine, pethi-
dine, alfentanil and sufentanil, varies among patients by
factors of 5–10 (7–9). Furthermore, despite the fact that
most clinically used opioids are selective for m-opioid recep-
tors (OPRM1), as defined by their selectivity in receptor-
binding assays, patients may respond far better to one
m-opioid than another, both with respect to analgesic respon-
siveness and side-effects (10–12). As such, there is a substan-
tial need to understand biological and genetic basis for
inter-individual variability and develop new biological
markers that will provide valid and reliable predictions of
individual responses to opioid therapy.
Although environmental factors influence the responses to
opioids, genetic background plays a significant role (13–16).
OPRM1 is the major target of both endogenous and exogenous
opiate and has been shown to mediate both baseline nocicep-
tion and response to OPRM1 agonists (17,18). Both animal
and human studies have indicated that reduced basal nocicep-
tive sensitivity is associated with greater opioid analgesia
(19–21) and suggested genetic polymorphisms in the human
OPRM1 gene is the primary candidate source of clinically
relevant variability in opiate sensitivity and baseline nocicep-
tion (13–16).
An extensive search for functional OPRM1 polymorphisms
has identified a few alternative loci with a relatively high
allelic frequency, which can mediate a significant degree of
the variable clinical effects observed in a population (reviewed
in 16). These alternative loci were found in the promoter,
coding and intron regions of the gene, which are associated
with the diverse pharmacological and physiological effects
mediated by OPRM1 stimulation. However, among SNPs
with a relatively high reported allelic frequency, which can
mediate a significant degree of the variable clinical effects
observed in a population, only the A118G OPRM1 SNP
(Asp40Asn) has been repeatedly shown to have functional con-
sequences. This missense SNP changes the N-terminal region
amino acid asparagine to aspartic acid, which decreases the
number of sites for N-linked glycosylation of the MOR recep-
tor from five to four, providing strong rational for association
studies. Several studies have demonstrated a relationship
between the frequencies of the A118G OPRM1 genomic
polymorphisms and OPRM1-dependent phenotypes, including
responses to opiates (22–25) and variations in pressure pain
thresholds (26). However, only a small percentage of the
variability of related phenotypes has been explained and con-
flicting and/or inconsistent results have been reported (27).
Furthermore, investigations of the functional properties of
the 40Asn variant have produced inconsistent results. First,
the minor G allele has been reported to increase the affinity
of OPRM1 receptor variant for b-endorphin by 3-fold in
AV-12 cells and Xenopus oocytes (28). Other studies have
shown no differences in agonist binding, functional coupling
and internalization between transiently expressed receptor
variants and wild-type receptors in COS and HEK293 cells
(29,30). Additionally, even though the original findings
demonstrated greater functional activity of the G allele recep-
tor variant, a substantial reduction in the expression of the
variant allele at both RNA levels in human autopsy brain
tissues and RNA and protein levels in the stably transfected
cell lines has also been reported (30,31). Collectively, our
current understanding of the genetic basis for individual vari-
ations in opioids responses suggests a strong contribution of
other untested variables that may include genetic variants
outside of the OPRM1 locus or/and the existence of the
other functional SNPs within the OPRM1 gene locus and
possibly within other yet undiscovered functional elements
of the gene.
There is a growing body of evidence from rodent studies
that demonstrates an important role of alternatively spliced
forms of OPRM1 in mediating opiate analgesia (32–34).
The synergistic activities of these splice variants have been
proposed to explain the complex pharmacology of m-opioids
(35). Still, it is unclear whether the findings from rodent
studies are applicable to human opioid responses because of
a striking discrepancy between the genomic organizations of
the mouse and human OPRM1. According to the NCBI data-
base, the mouse OPRM1 gene consists of 20 exons and codes
for 39 alternative-spliced forms. In contrast, the human
OPRM1 gene consists of only nine exons and codes for only
19 alternative-spliced forms (Unigene database).
Here we show that almost all of the known mouse exons
have corresponding orthologs within the human OPRM1
gene locus and can be subject to genetic variability, which
modifies receptor function and associated phenotypes. Associ-
ation analysis of human allelic variations within these new
exons with quantitative measures of pain sensitivity and
responses to morphine identified a novel and potentially func-
tional SNPs in the human OPRM1 gene. Furthermore, we
cloned new human MOR-1K isoforms that carry SNP
rs563649, which is strongly associated with pain-sensitivity
phenotypes. We demonstrated that SNP rs563649 is located
within a structurally conserved internal ribosome entry site
(IRES) in the 50-UTR of these novel isoforms and affects
translational efficiency of these variants. Our results substan-
tially extend our knowledge of the OPRM1 gene locus and
introduce new targets for the development of genetic
markers, which may lead to individualized opioid-based
therapies.
RESULTS
Gene architecture of the human OPRM1
To identify human orthologs of mouse OPRM1 exons, we con-
firmed the synteny within the full-length sequences of the
human and mouse OPRM1 genes and analyzed patterns of
similarity in inter-species comparisons using detailed pairwise
alignments (36). We used mRNA sequences of known alterna-
tively spliced isoforms of mouse OPRM1 and GenBank anno-
tations to refine locations of the initial and terminal exons and
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to identify unknown human orthologous exons (37). In
addition, we performed an extensive search for regulatory
sites, structural elements and splicing signals (38–42) to
reveal putative sites of initiation and termination of transcrip-
tion and to refine exon/intron boundaries.
Results of our analysis suggest that most exons of the
OPRM1 gene annotated in the mouse also exist in primates
(Fig. 1A). Our results also predict new exon–intron bound-
aries (see Fig. 1B for exon 13 example), an alternative tran-
scription start site and conserved promoter (43,44) upstream
from the predicted primate exon 11 with conserved putative
transcription factor binding sites in primates and rodents
(Supplementary Material, Fig. S1). These data support the
existence of a larger and more complex human OPRM1
gene (Fig. 1).
To delineate the exact boundaries of the newly identified
human exons, pairwise comparisons and evolutionary rate
estimation were performed for different functional domains
of the gene using OWEN alignments (19). Evolutionary diver-
gence was estimated in separate pairwise alignments for
different functional domains of the OPRM1 gene (Ks, Ka, Ku
for exons and Ki for introns) for closely related rodent
(mouse and rat) and primate (human and macaca) species,
and for distantly related species (human and mouse). Both
flanking (50 nucleotides) and core regions of functional
domains were considered (Table 1). The analysis revealed sig-
nificant selective pressure associated with exonic regions and
their vicinities further supporting the existence of the
expanded human OPRM1 gene locus, which is 90 kb
longer than was thought previously. Analysis of evolutionary
divergence and conservation of regulatory splicing sites
suggest that some of the new exons in primates are extended
or shortened relative to rodent exons. These data are consist-
ent with the generally low conservation of exonic boundaries
in alternative splicing patterns in the human and mouse
genomes (45).
Association analysis between selected SNPs
and pain sensitivity
Having established the areas of exonic conservation within the
OPRM1 gene locus, we selected a set of 30 candidate SNPs
that potentially cover the functional allelic diversity of the
gene, with an emphasis on the newly identified exons and
promoter regions. Genotyping data were collected from 196
healthy Caucasian female volunteers, characterized for their
sensitivity to noxious stimuli by calculating a summary pain-
sensitivity score. From the examined 30 SNPs, five (rs1323040,
rs7775848, rs1799972, rs1042753 and 12205732) were
found to be monomorphic. The remaining 25 SNPs were ana-
lyzed. All markers were found to conform to Hardy–Weinberg
equilibrium, with the exception of the rs1294094 and
rs6912029, which were removed from the association analysis
(Table 2).
The pain-sensitivity score was calculated as follows. Each
participant in the analyzed cohort was quantified for respon-
siveness to a number of noxious modalities (thermal, mechan-
ical and ischemic) applied to various anatomical sites (46,47).
Because opioids such as morphine modify the perceptual
responses to all of the assessed noxious modalities (48–51),
we derived a unitary quantitative measure of pain sensitivity
for the quantitative analyses. To accomplish this, each of 16
measures of pain sensitivity was normalized to a mean of
zero and standard deviation of one, producing a unit normal
deviate (z-score) for each test procedure. A sum of these 16
scores produced a normalized single score of pain sensitivity
(summary z-score) for each individual (see Supplementary
Material for details). We thus hypothesized that population
variations in the constructed global measures of pain sensi-
tivity would be associated with functional genetic polymorph-
isms in OPRM1.
The relationships between OPRM1 genetic variants and
pain scores were first examined using overall tests for haploty-
pic associations with the composite haplotype method (CHM)
(52) in sliding windows of one to 12 SNPs (Table 3). The
CHM is designed for determining associations due to multiple
interacting SNPs and is applicable regardless of the linkage
disequilibrium (LD) between the tested SNPs. CHM is a flex-
ible extension of our earlier approach, termed the haplotype
trend regression (HTR) (53). The difference between the two
approaches lies in that the HTR considers joint frequencies
of alleles that reside on the same haplotype, whereas the
CHM considers the sum of joint frequencies that reside on
the same as well as on two different haplotypes within individ-
uals. Thus, the CHM is readily applicable to sets of SNPs that
span separate haplotype blocks. Moreover, while the CHM can
be used to detect haplotypic effects, it is also able to capture
epistatic effects due to interactions between two haplotypes
in a diplotype. We conducted two types of haplotype associ-
ation analysis. ‘Overall’ CHM tests in sliding windows of
varying size provide a single P-value for a set of SNPs in a
given window. Next, given the overall significance, tests for
individual haplotypes were conducted to determine specific
haplotypes to which the overall association was due. The indi-
vidual tests were carried out using the CHM as well as a
likelihood-based haplotype association method by Shibata
et al. (54,55). To make a comparison of the overall CHM
tests with the HTR, we replicated the analysis using the
HTR. The CHM appeared to have provided greater evidence
of association, which is possibly due to non-additive epistatic
interactions (data not shown).
Statistically significant association was found between the
pain-sensitivity score and SNP rs563649 in the sliding
window of size 1 (SW1), where the CHM becomes an
allelic trend test (P ¼ 0.0007). When SW2 was applied,
three significant associations were observed (Table 3). The
associations of the pain score with the haplotypes
rs3798678–rs563649 (P ¼ 0.0028) and rs563649–rs9322446
(P ¼ 0.0018) most likely reflect the effect of SNP rs563649
identified with SW1. Significant associations of the pain
score with the haplotype rs2075572–rs533586 (P ¼ 0.0007)
identified a new potentially functional genetic variant of
OPRM1. In each of the following SW approaches, associations
between the pain score and haplotypes were significant for
each haplotype containing SNPs rs563649, or haplotype
rs2075572–rs533586, or both. The associations for haplotypes
starting with either SNP rs563649 or SNP rs2075572 remained
significant after the Bonferroni correction for multiple testing
within each window size (P ¼ 0.0022 for the highest number
of tests for SW1 (Supplementary Material, Fig. S2).
Human Molecular Genetics, 2009, Vol. 18, No. 6 1039
Figure 1. The structure of the human and mouse OPRM1 gene. (A) Conventional structures of the mouse (upper panel) and human (middle panel) OPRM1 genes
are shown in accordance with the NCBI database, UCSC genome browser and published data (43,76,77). Our version of the structure of the human OPRM1 gene
(lower panel) is based on multispecies genome alignments created by OWEN (36) and comparative genomes analysis. Exons and introns are shown by vertical
and horizontal boxes, respectively. Shaded boxes represent constitutive exons. Maximal sizes of human exons (for lower panel) are shown in parentheses (nt):
exon 11 (206), exon 1 (580), exon T (117), exon 14 (105), exon 13 (1200), exon 2 (353), exon 3 (521), exon R (488), exon Y (109), exon 16 (314), exon X
(1271), exon 17 (128), exon 5 (1013), exon 4 (304), exon 18 (412), exon 6 (124), exon 7 (89), exon 9 (393). (B) Alignment of human (1), chimpanzee (2),
macaca (3), rat (4) and mouse (5) exon 13 and its conserved vicinity regions. Splicing boundaries are indicated by vertical bars. Enhancers of splicing (39)
near exon–intron boundaries are marked in yellow. SNP rs563649 is highlighted in red. Conserved nucleotides for all species are marked by stars. Structurally
conserved IRES in the human sequence is marked by green. Predicted uORFs in the human sequence are marked by arrows.
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Association analysis in the second cohort
The association between pain responses and SNP rs563649 was
tested in an independent cohort of healthy Caucasian subjects
recruited at the University of Florida. Because of the smaller
cohort size (n ¼ 133) and necessity to control for gender in
this cohort, limited genetic analyses were conducted. Only
SNP rs563649 was chosen for an exploratory analysis because
it exhibits the strongest individual contribution to the associ-
ations and can be considered as a marker of a functional haplo-
type. Analysis of covariance was used to examine the association
of the rs563649 SNP with the summed z-pain scores. This analy-
sis determined whether summed pain scores for individuals with
one or two copies of minor alleles (n ¼ 21) differed from those
of individual homozygous for the major allele (n ¼ 112), after
controlling for age and gender. In agreement with association
in the first cohort, the minor allele group had higher z-scores
than the major allele group [0.63 (1.19) versus 20.95 (0.52)],
(Supplementary Material, Table S2), although this difference
did not reach statistical significance.
Furthermore, in a subset (n ¼ 68) of this cohort, the analge-
sic effect of morphine on experimental pain sensitivity was
assessed, which allowed us to examine associations between
OPRM1 SNPs and m-opioid analgesia. Subjects reported
ischemic pain threshold, and then at 1 min intervals, subjects
rated the intensity and unpleasantness of ischemic arm pain,
induced via the submaximal effort tourniquet procedure,
before and after the intravenous administration of 0.08 mg/kg
of intravenous morphine. The submaximal effort tourniquet
procedure was chosen for analgesic assessment because it is
among the most sensitive to OPRM1-mediated analgesia (56)
when compared with other experimental pain assays. First,
the difference in ischemic threshold before and after drug
administration was assessed. Then, as described previously
(50), summed scores for ratings of pain intensity and unplea-
santness across the duration of the tourniquet procedure were
computed before and after drug administration. Change scores
for summed pain intensity ratings were computed by subtract-
ing the post-drug summed score from the pre-drug summed
score, such that larger values indicate a greater reduction in
pain following morphine administration, thus greater analge-
sia. Subjects with one or two rare alleles T of rs563649
showed less analgesia than homozygotes for the major allele
C, with P-values approaching statistical significance, ranging
from 0.054 to 0.09 (Supplementary Material, Table S2).
The direction of effects was the same for both cohorts and
the effect sizes was quite similar for basal pain sensitivity,
although the association results in the second cohort did not
reach significance. Furthermore, carriers of the minor T
allele showed poor responses to morphine, consistent with
higher sensitivity to pain demonstrated by these subjects and
further suggesting functional significance of SNP rs563649.
Reconstruction of functional haplotypes
We then hypothesized that different SNPs may belong to
the same functional haplotype associated with increased pain
sensitivity. The analysis of the constructed LD matrix using
the Haploview program showed that the 23 analyzed SNPs
were located in two separate haplotype blocks (Supplementary
Material, Fig. S3). SNPs rs7776341–rs3798678 are in Block I
and SNPs rs563649–rs497332 are in Block II, which is
consistent with previously published reports (57). rs563649
(C/T) is situated on the border of two haploblocks, displaying
very high LD with SNPs in both haploblocks (Supplementary
Material, Fig. S3).
We first evaluated the haplotypes containing SNPs rs563649
(C/T), rs2075572 (G/C) and rs533586 (C/T), which appear to
be the minimal functional units. The sampling LD values
between these SNPs can be determined directly from the
haplotype frequencies, which were estimated with the
expectation-maximization (EM) algorithm, and are given in
Table 4. The three D0 values in this case are all very high
(0.8, 1, 20.92) (Supplementary Material, Fig. S3). The haplo-
type T-C-T in this 3-loci set was significantly associated with
pain sensitivity, as shown by a conservative P-value estimate
calculated under different models (52) (Table 4). This haplo-
type was associated with significantly higher pain ratings
(z = 4.83) and was observed in 6% of the subjects. We
next examined whether SNPs within the OPRM1 gene locus,
which have been previously reported to be associated with
pain, analgesia or other pain-related phenotypes, are related
to the pain-sensitivity haplotype established by our analysis.
SNP rs1799971 (A118G) has been repeatedly shown to
produce functional effects. Carriers of the minor 118G allele
Table 1. Divergence in exons and introns of rodent and primate OPRM1
genes*
CDSs/UTRs Upstream intron Downstream
intron
Ka Ks or Ku 3
0_50 Central 50_50 Central
Mouse–rat
Exon 11 — 0.116 — — 0.131 0.199
Exon 1 0.031 0.118 0.110 0.173 0.114 0.136
Exon 13 — 0.146 0.109 0.177 0.063 0.171
Exon 2 0.004 0.317 0.134 0.171 0.041 0.129
Exon 3 0.005 0.316 0.131 0.129 0.185 0.173
Exon 18 0.079a 0.176/0.113a 0.161 0.187 0.087 0.165
Human–Macaca
Exon 11 — 0.040 — — — 0.068
Exon 1 0.014 0.014 0.020 0.068 0.064 0.062
Exon 13 — 0.071 0.109 0.064 0.064 0.074
Exon 2 0.004 0.051 0.085 0.074 0.041 0.057
Exon 3 0.005 0.069 0.042 0.057 0.054
Exon 18 — 0.063 0.041 0.069 0.020 0.065
Mouse–human
Exon 11 — 0.378 — — 0.458 0.632
Exon 1 0.100 0.465 0.218 0.632 0.579 0.773
Exon 13 — 0.433 0.352 0.502 0.667 0.608
Exon 2 0.007 0.563 0.517 0.608 0.420 0.481
Exon 3 0.011 0.903 0.240 0.481 0.574 0.530
Exon 18 — 0.847 0.134 0.535 0.383 0.579
Evolutionary rates at non-synonymous (Ka) and synonymous (Ks) sites
were calculated for coding exons by PAML (69). Evolutionary rates at
non-coding exons (Ku) and for intronic sequences (Ki) were calculated
using Kimura’s two-parameter model (70). The Ki values for central parts
and for the end 50 nucleotide regions (30_50 and 50_50) of introns were
calculated separately, because 50 nucleotide sequences at each end of an
intron are thought to be subject to weak purifying selection that stems from
the involvement of these sequences in splicing (39,78).
aFor partially coding exons, Ka and Ks were calculated for cording parts and Ku
was calculated for non-coding sequences.
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show decreased analgesic responses to morphine and M6G
(22–25) and significantly higher pressure pain thresholds
(26). In our dataset, homozygotes for the G allele tended to
have the lower mean pain scores, whereas homozygotes for
the A allele tended to have the higher mean pain scores (data
not shown), but this difference did not achieve significance.
We also considered rs495491, which has been associated with
pain-related mood scores (58), and rs609148, which along
with rs495491 has been shown to be associated with substance
dependence, including opioid dependence (57). We evaluated
the 6-loci haplotypes consisting of the three core SNPs estab-
lished by our analysis and three SNPs described in the literature:
rs1799971 (A/G), rs495491 (A/G), rs563649 (C/T), rs2075572
(G/C), rs533586 (C/T) and rs609148 (G/A). The D0 values
between rs563649 and this set of SNPs are also very high
(1, 1, 0.81, 1, 1, 1) (Supplementary Material, Fig. S3). The
6-loci haplotype A-G-T-C-T-G was also found to be signifi-
cantly associated with higher pain scores (z ¼ 4.83) and was
also observed in 6% of the subjects (Table 4). Importantly,
the most significant haplotypic test in Table 4 is flagged by
both the EM-based method and the CHM.
Identification of human MOR-1K isoforms
To identify molecular biological mechanisms whereby associ-
ated SNPs may affect OPRM1 function, we first examined
its position relative to newly identified OPRM1 structural
elements. SNP rs563649, the strongest contributor to the
pain-sensitivity phenotype, was located in the evolutionarily
conserved footprint of the OPRM1 gene downstream from the
predicted human exon 13, which is not represented in known
human and mouse transcripts. Comparative sequence analysis
showed the absence of conserved 30-splicing sites and intro-
nic/exonic enhancers in the vicinity of predicted human exon
13 region, suggesting that rs563649 may be situated within a
novel human exon that extends downstream in primate lineages
relative to rodents (Fig. 1B, Table 1). To test this hypothesis, we
performed RT–PCR using RNA isolated from the human brain
tissues (Supplementary Material, Table S3), which express high
levels of OPRM1 and are known to respond to opioid treatment.
The forward primers were designed to predicted exon 13 and
reverse primers to exon 2 (Fig. 2A–C; Supplementary Material,
Table S4). RT–PCR results showed that the human exon 13 is
0.8 kb longer than the mouse exon 13 and carries alternative
acceptor sites of splicing (Supplementary Material, Fig. S4)
similar to OPRM1 exons 1, 3 and 5 (35,43). The sequencing
results of the RT–PCR product amplified from the frontal
lobe, nucleus accumbens, medulla oblongata and spinal cord
identified a 50-UTR and a partial coding region of novel
OPRM1 splicing isoforms, MOR-1K1 and MOR-1K2
(GenBank accession nos EU362990 and EU360599). A
longer MOR-1K1 variant is preferentially expressed in the
Table 2. Candidate polymorphism in OPRM1 gene locus




Potential functional significanceb Minor allele
frequency
1 rs1319339 T . C 50 intragenic mMOR-1G-N N/A 700 nt upstream of conservation for
exon 11
0.16
2 rs7776341 A . C 50 intragenic mMOR-1J N/A Within human analog of mouse
exon 12
0.042
3 rs1074287 A . G 50 intragenic mMOR-1J N/A Within human analog of mouse
exon 12
0.264
4 rs1799971 Asp40Ans A . G First exon all exc mMOR1-K-L all exp mu3 Non-synonymous 0.131
5 rs524731 C . A First intron 0.17
6 rs495491 A . G First intron 0.267
7 rs1381376 C . T First intron 0.174
8 rs3798678 A . G First intron mMOR1-L N/A Within human analog of mouse
exon 14
0.16
9 rs563649 C . T First intron mMOR1-K hMOR1-K1,
hMOR1-K2
Within extended human analog of
mouse exon 13
0.078
10 rs9322446 G . A First intron mMOR1-K N/A Within human analog of mouse
exon 13
0.169
11 rs2075572 G . C Second intron 0.386
12 rs533586 T . C Third intron mMOR1-E-F N/A 0.238
13 rs540825 His464Gln A . T Exon X N/A hMOR1-X Non-synonymous 0.238
14 rs675026 Gly503Gly G . A Exon X N/A hMOR1-X Synonymous 0.341
15 rs660756 T . G Exon Y mMOR1-C,F,M,N,S hMOR1-Y 30-UTR 0.352
16 rs677830 stop388Gln C . T Exon 5 mMOR1-B hMOR-1B Non-synonymous 0.236
17 rs650245 G . A Exon 5 mMOR1-B hMOR-1B 30-UTR 0.103
18 rs623956 A . G Exon 5 mMOR1-B hMOR-1B 30-UTR 0.414
19 rs609148 G . A Exon 5 mMOR1-B hMOR-1B,Y 30-UTR 0.233
20 rs497332 C . G Exon 5 mMOR1-B hMOR-1B,Y 30-UTR 0.089
21 rs648893 A . G Third intron 0.229
22 rs7759388 G . A Exon 7 mMOR1-C,E,F,M,O,Q hMOR-1O 20 nt upstream of exon O 0.141
23 rs9322453 G . C Exon 7 mMOR1-C,E,F,M,O,Q hMOR-1O 150 nt downstream of exon O 0.402
aIn accordance with current NCBI human OPRM1 locus.
bIn accordance with our prediction of extended OPRM1 locus.
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medulla oblongata, while a shorter MOR-1K2 variant preferen-
tially expressed in the spinal cord. Both these variants are
present in the frontal lobe and in nucleus accumbens (Sup-
plementary Material, Table S5). We found no evidence of the
expression of an isoform containing a short exon 13 in
humans or an isoform with a long exon 13 in mouse.
To establish the complete coding region of MOR-1K iso-
forms, we performed RT–PCR reactions with the forward
primer situated at exon 13 and reverse primers located at
exons 4, 7, 8 or X. Only the form containing exons 13, 2, 3
and 4 was amplified (Fig. 2D), consistent with the mouse
MOR-1K form (43). Again, consistent with the mouse
MOR-1K, translation of these new isoforms seems to be
initiated at the first AUG in exon 2, as all upstream reading
frames code for short peptides. Consequently, both human
MOR-1K1 and MOR-1K2 isoforms encode a truncated
version of OPRM1 that lacks an extracellular N-terminal
domain and transmembrane domain I. To identify the tran-
scriptional start site of MOR-1K isoforms, we performed
50RACE PCR. The 50 start site has been mapped to a novel
OPMR1 promoter region that is located upstream of exon 13
(Supplementary Material, Fig. S5), unlike the mouse
MOR-1K isoform where transcription is initiated from an
alternative promoter upstream to exon 11 (43).
Effect of rs563649 on MOR-1K expression
To understand how SNP rs563649 can affect the expression or
function of the MOR-1K isoforms, we searched for functional
regulatory elements within the 50-UTR of MOR-1K transcripts.
We found that this functional variation is located within a
structurally conserved IRES in the 50-UTR of MOR-1K
transcripts (Fig. 3A). This IRES is conserved in human and
chimpanzee, but absent in rodents. Stems II and III in IRESs
can participate in coaxial stacking within a common Y-type
structure and are likely required for ribosome binding to
IRES (41). Nucleotides in loops II and III may interact with
each other (‘kissing hairpins’) or with ribosomal proteins,
which can result in altered binding of ribosome to IRES
and, consequently, affect translation through a ‘zipper’ mech-
anism (41). It has been shown that precise secondary structure
is important for the function of IRESs. A single nucleotide
substitution producing structural changes in the c-myc
IRES resulted in increased translation initiation by internal
ribosome entry and was associated with oncogenesis (59).
SNP rs563649 is located in the IRES loop II, where the
major allele C likely allows a better base pairing between
loops II and III (AAC:GUU) than the minor allele T
(AAU:GUU) (Fig. 3A). To examine effects of rs563649
Table 3. P-values of the association between 23 OPRM1 SNPs and pain scores
Mar-ker no. NSBI SNP Id SNP location sw1 sw2 sw3 sw4 sw5 sw6 sw7 sw8 sw9 sw10 sw11 sw12
1 rs1319339 700 nt upstream of
conservation for
exon 11
0.0984 0.1651 0.3228 0.5066 0.3036 0.4252 0.1758 0.1077 0.0722 0.0211 0.0059 0.0111
2 rs7776341 Within human ortholog
of mouse exon 12th
0.3297 0.3512 0.5331 0.4185 0.4960 0.1421 0.0695 0.0609 0.0239 0.0190 0.0057 0.0050
3 rs1074287 In human ortholog of
mouse exon 12th
0.2038 0.3817 0.3682 0.6145 0.2332 0.1182 0.1322 0.0490 0.0212 0.0056 0.0075 0.0124
4 rs1799971 Exon 1, non-synonymous 0.4577 0.6893 0.5157 0.2327 0.0936 0.1175 0.0529 0.0473 0.0029 0.0078 0.0081 0.0101
5 rs524731 0.5582 0.6553 0.0926 0.0302 0.0563 0.0571 0.0826 0.0090 0.0086 0.0119 0.0558 0.0872
6 rs495491 0.2120 0.0246 0.0107 0.0249 0.0307 0.0463 0.0004 0.0057 0.0050 0.0256 0.0196 0.0130
7 rs1381376 0.2787 0.4471 0.0025 0.0189 0.1155 0.0036 0.0057 0.0064 0.0061 0.0061 0.0033 0.0058
8 rs3798678 Within human ortholog of
mouse exon 14th
0.3433 0.0028 0.0045 0.0455 0.0125 0.0050 0.0057 0.0139 0.0057 0.0033 0.0038 0.0034
9 rs563649 In human ortholog of
mouse exon 13th
0.0007 0.0018 0.0083 0.0053 0.0080 0.0065 0.0126 0.0084 0.0021 0.0024 0.0014 0.0022
10 rs9322446 Within human ortholog of
mouse exon 13th
0.0941 0.1515 0.0036 0.0058 0.0066 0.0057 0.0044 0.0029 0.0034 0.0009 0.0013 0.0099
11 rs2075572 0.2957 0.0007 0.0005 0.0013 0.0019 0.0024 0.0010 0.0013 0.0003 0.0005 0.0068 0.0269
12 rs533586 0.7037 0.9993 0.5884 0.5452 0.5848 0.8374 0.9692 0.2263 0.3518 0.9986 0.4128 0.9421
13 rs540825 Exon X, non-synonymous 0.8171 0.9956 0.4866 0.5395 0.9051 0.9633 0.2268 0.3038 0.2340 0.0839 0.7335
14 rs675026 Exon X, synonymous 0.8012 0.4568 0.5673 0.5888 0.8847 0.5151 0.4278 0.4571 0.1147 0.8005
15 rs660756 Exon Y, 30-UTR 0.5745 0.9027 0.5625 0.8062 0.9616 0.9239 0.3289 0.0853 0.3573
16 rs677830 Exon 5, non-synonymous 0.9891 0.7803 0.8374 0.9662 0.9242 0.9131 0.3746 0.8369
17 rs650245 Exon 5, 30-UTR 0.3723 0.7961 0.9525 0.8791 0.3508 0.3916 0.7837
18 rs623956 Exon 5, 30-UTR 0.8308 0.9267 0.9286 0.9808 0.4276 0.4391
19 rs609148 Exon 5, 30-UTR 0.8208 0.6893 0.9664 0.2838 0.5825
20 rs497332 Exon, 30-UTR 0.3139 0.7817 0.1362 0.3025
21 rs648893 0.5043 0.4306 0.6341
22 rs7759388 20 nt before exon O 0.5425 0.7773
23 rs9322453 150 nt after exon O 0.9195
sw, sliding window; P-value reflects associations between pain phenotype and haplotype that starts from the indicated SNP within the corresponding
window size. Values marked in italic represent the potential effect of SNP rs563649. For example, P ¼ 0.0722 marked in italic in the first row represents
a 9-SNP haplotype that includes rs563649 as its ninth SNP. Similarly, values marked in bold represent potential combined effects of SNPs rs2075572 and
rs533586; and values marked in italic and bold represent potential effects of both functional sites—SNPs rs563649 and rs2075572–rs533586. The
association has replicated in all of the fixed-size windows (Supplementary Material, Fig.1S). Even though the tests in the sliding windows of different
sizes are not independent, the association results were consistent across all graphs, reinforcing the evidence for association in the region.
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allelic variants on translation efficiency, we transiently trans-
fected human neuroblastoma BE2C cells with reporter con-
structs that carried allelic variants of MOR-1K IRES inserted
between transcription and translation start sites (Fig. 3B).
Similar to the published report (59), the T allelic variant of
MOR-1K IRES showed significantly higher translational
activity than the C allelic variant (Fig. 3). As the T allelic
variant also produced lower mRNA levels (Fig. 3C), these
results suggest reciprocal allelic regulation of MOR-1K at
the RNA and protein levels, where the T allele leads to
increased translational activity, through the increased ribo-
some binding and the C allele provides higher RNA levels,
probably due to decreased accessibility for nucleases.
DISCUSSION
In this study, we performed an extensive search for functional
SNPs within the OPRM1 gene locus and made several funda-
mental observations. First, we identified several novel and
potentially functional SNPs. Particularly, a novel SNP
rs563649, which is situated within the newly identified exon
13, was the strongest independent contributor to measured
pain-sensitivity responses (Table 3). In contrast to SNP
rs563649, the SNPs that have been previously associated
with OPRM1-dependent phenotypes displayed rather modest
effects. Specifically, the non-synonymous SNP variant
A118G (Asp40Asn), which has been shown to be associated
with human pressure pain thresholds (26), showed much
smaller differences. In agreement with previous findings, in
our cohorts homozygotes for the G allele displayed the
highest mean values for mechanical pain thresholds, whereas
homozygotes for the A allele displayed the lowest mean
values for mechanical pain thresholds; however, this differ-
ence did not reach significance (data not shown). Importantly,
the previously published association achieved statistical sig-
nificance only among males (26), whereas our cohort tested
for experimental pressure pain consisted of females only.
Further, we have identified a potentially functional haplo-
type associated with high pain sensitivity (Table 4), which is
tagged by the minor allele T of rs563649. The frequency of
this haplotype corresponded to the frequency of the minor T
allele and the SNP rs563649 was the strongest individual con-
tributor to the association, suggesting that the minor T allele of
this newly identified SNP is a strong candidate for the func-
tional site of the haplotype. This haplotype spans over the
OPRM1 gene locus and consists of all the alleles that have
previously been shown to be associated with lower pain
thresholds (rs1799971, A allele) (26), negative mood
(rs495491, G allele) (58) and increased substance dependency,
including opioid dependence (rs609148, G allele and
rs495491, G allele) (57), all of which are consistent with a
low level of opioid receptor activity. On the other hand,
whereas the T allele of rs563649 in our cohort is associated
with a decreased analgesic response to opioids, again consist-
ent with low levels of receptor activity (21), the A allele of
rs1799971, which is situated on the haplotype tagged by the
T allele of rs563649, is associated with an increased analgesic
response to opioids (16).
Together, our data give rise to the possibility that some of
the previously reported positive associations can be explained,
Table 4. Results for the haplotype association tests









T-C-T 0.0618 4.8352 0.0091412 0.0015397 0.0019992 0.000434
T-G-T 0.0086 9.1966 0.063606 0.17987 0.06579 0.003562
C-C-T 0.0029 11.4524 0.17837 0.40429 0.17976 0.01999
C-C-C 0.3036 20.2021 0.76821 0.41499 0.3979 0.317572
C-G-T 0.6077 0.1275 0.66807 0.011332 0.10761 0.038788
C-G-C 0.0154 6.491 0.072587 0.19909 0.0760661 0.155424
Overall P-value (CHM): 0.00085
Six loci haplotypese
A-A-C-G-T-G 0.3933 20.1934 0.69931 0.70015 0.4836 0.142904
A-A-C-C-C-A 0.2117 20.1473 0.86488 0.89225 0.99428 0.772462
G-A-C-G-T-G 0.1413 20.7922 0.45275 0.74980 0.4836 0.208048
A-G-C-C-C-G 0.0709 20.9320 0.57531 0.85486 0.8878 0.66288
A-G-C-G-T-G 0.0700 20.8657 0.61306 0.27691 0.4191 0.467318
A-G-T-C-T-G 0.0620 4.8228 0.0092318 0.0015490 0.0020254 0.000724
A-G-C-C-C-A 0.0138 22.5697 0.49803 0.79497 0.9430 0.196706
A-A-C-G-C-A 0.0123 6.6722 0.099676 0.25788 0.8648 0.1029
A-G-T-G-T-G 0.0087 9.0049 0.066064 0.18471 0.8711 0.013182
A-G-C-G-C-G 0.0062 1.5232 0.77968 0.96253 0.9851 0.391084
A-A-C-C-C-G 0.0059 214.462 0.016594 0.056738 0.86036 0.091284
A-A-C-C-T-G 0.0030 11.2606 0.18682 0.41846 0.1881 0.128432
G-G-C-G-C-G 0.0007 4.0258 0.75442 0.95227 0.9936 0.794988
Overall P-value (CHM): 0.005692
aFrequency, sample haplotype frequency.
bMean, the estimated mean effect value for the presence of one or two copies of a given haplotype.
cDominant, diplotype, additive, haplotype analysis models.
drs563649, rs2075572 and rs533586.
ers1799971, rs495491, rs563649, rs2075572, rs533586 and rs609148.
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at least in part, by the high LD between the reported markers
and the SNP rs563649 identified in this study (57,58). Further-
more, it is likely that several functional SNPs co-exist within
the haplotype, where alternative alleles play specific roles in
distinct but related pain phenotypes, are carefully balanced
and thus transmitted jointly. This haplotype was observed in
6% of the subjects, thus representing a substantial proportion
of the human population and is of clinical significance.
It should be noted that our association analysis has been
conducted on two moderately sized cohorts. The primary
results were obtained in the larger UNC cohort that consisted
of a homogeneous sub-sample of Caucasian females. The
second UF cohort is smaller and consists of both genders.
Although the association tests were highly significant in the
first cohort only, and it is important to replicate our results
in larger cohorts, the direction of effects was the same for
both cohorts with respect to pain sensitivity, and associations
with morphine response phenotypes were in the expected
direction, suggesting that the T allele codes for a low-
efficiency receptor variant. Furthermore, the validity of our
findings is supported by molecular biology experiments pre-
sented here, which demonstrate the existence of human exon
13 and a functional effect of the identified SNP rs563649.
To understand how the newly identified SNP may produce
functional effects, we constructed a reporter vector that
includes the entire predicted IRES element. Although the
exact molecular mechanism by which rs563649 regulates
OPRM1 function and pain signaling requires further studies,
out data suggest that the presence of minor T allele should
lead to higher expression levels of corresponding MOR-1K
isoforms. Furthermore, the localization of a strong functional
SNP within the human analog of mouse exon 13 provides evi-
dence for the biological significance of MOR-1K isoforms. We
showed that MOR-1K isoforms with variable exon 13–exon 2
junctions are expressed in a tissue-specific manner and likely
contribute to tissue-specific post-transcriptional regulation.
Because the T allele of rs563649 is associated with higher
translation efficiency and higher pain sensitivity, we suggest
that the truncated MOR-1K form contributes to hyperalgesic-
like rather than analgesic states and plausibly represents one of
Figure 2. Expression pattern of exon 13 containing OPRM1 gene splice variant in human and mouse. (A) The schematic diagram illustrates relative positions of
PCR primers designed to amplify the new alternative MOR-1K variants in mouse and human. The arrow indicates the relative position of SNP rs563649. (B)
RT–PCR was performed on total RNA samples from the human brain regions known to express OPRM1 with hU2 and hL5 primers specific for exons 13 and
exon 2, respectively. The exon 13 containing OPRM1 gene splice variant MOR-1K was detected in CNS but not in peripheral leukocytes even after a secondary
PCR round with nested PCR primers. The PCR product size was 1229 nt, which was three times longer than the predicted 385 nt based on homology with the
mouse genome. (C) RT–PCR analysis of mouse spinal cord with primer pairs mU2-mL3 and mU2-mL1 yielded PCR products of predicted size. A longer mouse
isoform orthologous to human exon 13 was below the level of detection even by secondary PCR with the nested PCR primers mU3-mL3, mU3-mL1 or
mU3-mL2. (D) The schematic diagram illustrates the exonic composition and relative positions of PCR primers designed to amplify the major MOR-1
variant and the newly identified alternative MOR-1K variant. The arrows indicate relative positions of translation initiation start codons and stop codons. (E)
The predicted protein structure of MOR-1 and MOR-1K isoforms. Translation of the MOR-1K variants results in a 6 transmembrane domain (6TM) receptor,
truncated at the N-terminus. (F) RT–PCR results demonstrate the relative expression pattern of human MOR-1 (primers hU1-L3) and MOR-1K (primers
hU5-L3) variants. GAP3DH was used as a control for cDNA loading. All major PCR products shown in this figure were sequenced and aligned with human
or mouse genomes.
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the molecular mechanisms underlying the excitatory effect of
opiods, contributing to tolerance, drug dependence and
opioid-induced hyperalgesia (60–62). Furthermore, simi-
larities in the tissue-specific expression patterns between
MOR-1 and MOR-1K, with lower abundance of MOR-1K rela-
tive to MOR-1 isoforms, support the possibility of a regulatory
function for MOR1-K. To date, no systematic studies invol-
ving the genetics, molecular and cell biology of this form of
OPRM1 receptor have been reported; and its biological func-
tion clearly warrants further research.
We also have shown that almost all of the known mouse
exons have corresponding orthologs within the human
OPRM1 gene locus and thus the genetic structure of human
OPRM1 is much more complex than is currently appreciated.
According to recent studies, at least 50% or more of human
genome is expressed in alternatively spliced isoforms (63).
There is a number of both computational and molecular biologi-
cal difficulties that make computational predictions and cloning
of the genetic variants of OPRM1 highly challenging. The
novel approaches used in this study overcame these difficulties.
The discovery of a much more complicated receptor structure
makes possible new interpretations of existing results and
permits the generation of novel testable hypotheses in diverse
disciplines that have interest in studying the OPRM1 function.
Figure 3. Allelic variants of structurally conserved IRES in exon 13 of human OPRM1. (A) The local stem-loop structure associated with putative IRES within
the 50-UTR of OPRM-1K isoform. The major allele C of SNP rs563649 is shown in red. Translation start codon of downstream uORF is shown in blue. (B) A
cloning of putative IRES allelic variants into secreted alkaline phoshatase (SEAP) reporter vector and associated translation detection experiments. (C and D)
The expression of IRES-SEAP constructs transiently transfected into human neuroblastoma BE2C cells. Relative mRNA (C) and SEAP activity (D) levels were
measured 8, 24 and 48 h after transfection. Reporter construct with the T allele showed significantly higher SEAP activity than reporter construct with the C
allele, although mRNA levels of construct with the C allele were significantly higher than those with the T allele (P , 0.05, n ¼ 4), suggesting higher translation
activity of the IRES T allelic variant.
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Genomic organization of the expanded human OPRM1
locus is highly similar to the organization of the mouse
OPRM1 locus. However, alternative splicing events within
this locus display some substantial differences between
human and mouse, and thus findings from rodent studies
should be considered with caution when applied to the func-
tion of human opioid receptor. Specifically, our RT–PCR
and 50RACE data suggest that exon 13 containing OPRM1
mRNA variants in human and mouse are highly divergent
(Fig. 2A–C; Supplementary Material, Fig. S5). New tissue-
specific alternative splice isoforms increase functional diver-
sity of the gene and create additional options for regulation,
as demonstrated by the strong effect of SNP rs563649 on
pain sensitivity (64). Importantly, location of this functional
SNP in a region of variable inter-species conservation shows
that biological function does not always correlate with
sequence conservation.
Our results also suggest that newly discovered alternative
exons, rather than constitutive exons, may represent targets
for genetic variability which modifies OPRM1 receptor func-
tion. Since modifications of the function of the main receptor
form may have dramatic consequences on fitness and may not
reach significant frequency in the general population, genetic
variations in alternative exons that are expressed at low
levels or only under specific conditions may lead to more
subtle phenotypic differences that underlie the observed vari-
ation in OPRM1-dependent phenotypes. Furthermore, our data
and methodological approaches are of relevance to genome-
wide association studies when SNPs associated with clinical
phenotypes are located in genomic areas that are devoid of
known structural genetic elements (65).
In summary, the identification of a potentially new func-
tional SNP with a substantial minor allele frequency within
alternative exons of OPRM1 is of considerable importance
to the field of pain genetics. Although the association of
SNPs rs563649 with sensitivity to noxious stimuli and
morphine responses requires further confirmation in larger
cohorts, our results provide strong evidence that this SNP
has a far greater effect on receptor function than other cur-
rently known OPRM1 polymorphisms. Collectively, our data
open conceptually new approaches to examining the structure
and function of the OPRM1 gene.
MATERIALS AND METHODS
First cohort description
One hundred ninety six (196) healthy European American
pain-free females with an age range of 18–34 years were gen-
otyped and phenotyped. Demographic characteristics of the
cohort at the time of recruitment were previously described
(47). This study was nested within a larger prospective study
conducted at the University of North Carolina at Chapel
Hill, which was designed to examine whether pain sensitivity
is a risk factor for the development of TMJD (47). Subjects
were phenotyped with respect to their sensitivity to pressure
pain, heat pain and ischemic pain. Indices of the temporal
summation of heat-evoked pain were also examined. The
detailed description of phenotypic procedures can be found
in Supplementary Materials. Each enrollee in the analyzed
cohort was quantified for responsiveness to a set of 16
noxious stimuli applied to various anatomical sites.
Second cohort description
The second cohort was recruited at the University of Florida
at Gainesville. Subjects included 133 healthy European
American volunteers (80 females, 53 males) recruited by
posted advertisements from the local community. In a subset
of this cohort (n ¼ 68, 40 females, 28 males), the analgesic
effect of morphine on experimental pain sensitivity was also
assessed. The experimental pain procedures were similar to
those described for the UNC cohort and can be found in the
Supplementary Material.
Computer analyses of genomic sequences
We used known alternatively spliced forms of mouse OPRM1
(MOR-1B, MOR-1F, MOR-1I, MOR-1J, MOR-1K and
MOR-1L, MOR-1Q, MOR-1S, MOR-1T, MOR-1R,
MOR-1P, MOR-1V and MOR-1W) from GenBank annota-
tions (http://www.ncbi.nlm.nih.gov/) to locate unidentified
human orthologous exons. Annotated alternative mouse and
human variants from altervative splice database (http://www.
ebi.ac.uk/asd) and UCSC database (http://genome.ucsc.edu/)
were also used in the analysis. BLAST (66) and BLAT
(http://genome.ucsc.edu/) were used to confirm the synteny
of aligned full-length sequences of the human and mouse
OPRM1 genes. Detailed alignments of orthologous pairs of
the human and mouse OPRM1 genomic and mRNA sequences
were produced using OWEN (36). For the CDS, the alignment
of the nucleotide sequences was guided by the amino acid
sequence alignment (67). Multiple alignments of nucleotide
sequences were constructed using the CLUSTALW program
with default parameters (68) and edited to take into account
results of pairwise comparisons, which was done using the
OWEN program (36). In all cases, our alignments contained
putative exons presented in GenBank. We masked sequences
using RepeatMasker (http://humangen.med.ub.es/tools/
RepeatMasker.html), because numerous low-complexity and
repetitive regions in long intronic sequences obscured the
pattern of orthology. All predicted primate transcripts were
analyzed by GENSCAN (http://gnomic.stanford.edu/ http://
CCR-081.mit.edu/GENSCAN.html). Modified UNCOVER
(42) approaches for the recognition of unknown conserved
alternatively spliced exons were used for extensive search of
regulatory sites and splicing signals. Two alternative
approaches for treating gaps (indels) in pairwise sequence
alignments were employed: (i) whenever a gap was introduced
in one of the sequences, the respective position in another
sequence was treated as a non-conserved one (a mismatch)
and (ii) positions containing one or more gaps were excluded
from the analysis (40). Evolutionary rates at non-synonymous
(Ka) and synonymous (Ks) sites were calculated for coding
exons using program PALM (69). Evolutionary rates at
non-coding exons (Ku) and for intronic sequences (Ki) were
calculated using Kimura’s two-parameter model (70). We per-
formed a search for regulatory sites and splicing signals using
the TRANSFAC database (http://www.biobaseinternational.
com/pages/index.php? id=transfacdatabases). Rodent and
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primate 50-UTRs were computationally folded by program
Afold (71) to predict potential IRES stable structures. The pre-
dicted minimum free secondary structure energy was calcu-
lated using our implementation of the dynamic programming
algorithm described by Zuker (72), which employs nearest
neighbor parameters for the evaluation of free energy.
SNPs genotyping
The algorithm for the selection of new candidate SNPs and full
SNP description are presented in the Supplementary Material.
Briefly, we concentrated on the SNPs with relatively high
minor allele frequencies that are situated within potentially
functional sites relative to known constitutive and predicted
alternative exons (Table 2). Genomic DNA was purified using
QIAampTM 96 DNA Blood Kit (Qiagen, Valencia, CA, USA).
The primers and probes for genotyping were from Applied Bio-
systems (ABI, Foster City, CA, USA) (Supplementary Material,
Table S1). The genotyping error rate was directly determined
and was ,0.005. Genotype completion rate was 95%.
Statistical analyses
We constructed summary statistics quantifying aspects of the
four pain modalities. Standardized z-scores for each pain
measure at each test site were computed by subtracting the
sample mean of the site-specific pain measure from the sub-
ject’s observed value, and dividing by the sample standard
deviation. The summary score was obtained by adding up
standardized z-scores.
Haplotype association methods
An overall test for association of a set of haplotypes with the
phenotype involves a specific set of k SNPs. The null hypothesis
of such a test is that none of the haplotypes defined by the k
SNPs is associated with the phenotype. When the haplotype
phase is unobserved, current methods incorporate specific
assumptions about the degree of deviation from Hardy–
Weinberg equilibrium. Here we employ a method that does
not depend on the HWE assumption. The approach is termed
the ‘composite haplotype method’, CHM (52). The idea
behind the CHM approach is best explained for the case of a
binary (e.g. case/control) phenotype. For two loci with alleles
(A, a) and (B, b), the ‘composite frequency’ is the sum of
intra-gametic, or haplotypic (PAB) and inter-gametic (PA/B)
frequencies (73). The advantage in considering the composite
sum is that unlike the haplotypic frequency, this sum is directly
estimated by counting from the unphased data. Thus, the HWE
assumption is not required, and furthermore, the uncertainty in
estimation of the composite frequencies is confined to just the
sampling variation and does not involve an error related to
the missing haplotype phase. This composite frequency (QAB
= [PAB+PA/B]/2) also forms the basis for the LD inference
by the composite disequilibrium approach (51). Instead of
comparing the haplotype frequencies themselves, as dh = PAB
(case) 2 PAB (control), the comparison in the CHM is based
on the composite difference, dc = QAB (case) 2 QAB (control).
Both differences are similarly expressed in terms of the
population frequencies (fi) and the susceptibilities (gi) for the
10 possible di-locus genotypes (AB/AB, . . . , AB/ab, Ab/aB, . . . ,
ab/ab). Denote the population prevalence by g. Then the







Note the similarity of the two equations. The terms of dc
would add up to dh exactly, if the term f6 (g62g)/2 that corre-
sponds to the cis-heterozygote, Ab/aB, was replaced by the
trans-heterozygote (AB/ab) term, f5 (g52g)/2. When AB is a
susceptibility haplotype, the term dh is positive, and so is dc.
In other words, the haplotypic and the composite frequency
differences are in the same direction for the ‘haplotype-driven’
models. We define haplotype-driven models to include reces-
sive, dominant, as well as intermediate models, notably the
additive model, where susceptibilities of AB heterozygotes
are between those for the genotypes with 0 and 2 copies of
AB. Whether the sign of dc is in the same direction as that
for dh is determined by the magnitude of the terms that corre-
sponds to the cis- and trans-genotypes, Ab/aB and AB/ab. The
condition that the dc is non-negative is satisfied for the
‘haplotype-driven’ models because of the constraints on
the population frequencies and the model susceptibilities.
Consider the recessive model: g1. g2; g2¼ g3 . . . ¼ g10.











½ð4þ f6Þ  ð4PAB þ f5Þðg1  g2Þ
is always non-negative, therefore, the signs of dh and dc are in
the same direction. This difference is similarly non-negative
for other haplotype-driven models. Thus, the composite differ-
ence can be used as a basis for testing haplotypic associations.
More generally, the composite difference provides a direct test
of association between sets of alleles across genetic loci and
the phenotype, without assuming HWE. Multilocus, multialle-
lic composite extension is obtained very simply. There are as
many composite frequencies as there are haplotypes, and the
notation for the composite classes is the same as that for the
haplotypes, e.g. ‘A2B1C1D1’ may refer to either a haplotypic
or a composite set of alleles (A2, B1, C1, D1) at four loci.
Denote a particular set of alleles such as this by Sk. The







where H(Gi) is the number of single-locus heterozygotes in
the multilocus genotype Gi of the ith individual, i=1, . . . ,n,
and I(.) is the indicator function that is equal to 1 if the ith
individual has alleles (Sk), and 0 otherwise.
For a continuous phenotype, the overall and the individual
test statistics for association are F-statistics in a linear
regression with the design matrix where columns indicate all
haplotype classes of interest, rows correspond to the individuals
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and entries are 1/H(Gi), the reciprocals of the individual’s
heterozygosity, or 0 if the genotype is incompatible with the
allele set corresponding to the column. For one locus, the test
reduces to the allelic trend test (53). As an association test for
joint frequencies of alleles across multiple loci, the CHM is a
valid test to detect allelic interactions between loci that are
involved in an association with the studied trait. The CHM
does not rely on LD between the loci and in fact can be used
to detect interactions among multiple loci with weak or no
LD. Moreover, Morris and Kaplan (74) showed that usage of
haplotype association methods might be advantageous under
weak LD, because single-locus-based approaches tend to
provide high power when the LD is strong. Further details of
the CHM will be described elsewhere.
Although CHM provides a robust test when haplotypic
association is present in a region, we are also concerned
with an unbiased estimation of effects for particular haplo-
types. Shibata et al. (54) suggested a parametric method that
provides estimates of haplotype effects as well as haplotype-
specific P-values based on a likelihood ratio test. A particular
model (diplotypic, additive, recessive, dominant or overdomi-
nant) needs to be specified prior to the analysis. A haplotype
would be flagged as an ‘associated’ if the significance persists
across all methods. When the same haplotype is tested by the
different methods, there is no need for a strict correction for
multiple testing, because the same hypothesis is being
tested. In this case, a conservative overall P-value for a par-
ticular haplotype is given by the maximum of the P-values
(diplotypic, dominant, additive and CHM). In fact, this gives
the upper bound for Simes’s adjustment/combination test
(75), which is applicable under positive dependence among
P-values, such as expected here. Haplotype frequencies were
estimated using a program described by Shibata et al.
(54,55), which implements the estimation via the EM
algorithm.
The flow of the haplotypic analysis was as follows: CHM
was used in a sliding window fashion, using window sizes
from one to 12 SNPs (W ¼ 1, . . . ,12), with the maximum
size pre-chosen to be equal to one-half of the number of
markers. Window size of one corresponds to the test of an
additive effect of an SNP (‘allelic trend test’). The
permutation-based overall test (100 000 permutations) of com-
posite allelic association was computed for each window, the
–ln(P-value) plotted and compared with the conservative Bon-
ferroni threshold that accommodates the number of tests in
each window. The tests involving the different W are not inde-
pendent, because they contain and share linked markers in LD.
Nevertheless, if significance of association persists across
windows of different sizes (as we indeed observed), the
overall confidence in the association should be increased.
Overall tests that showed a significant association were fol-
lowed by a more detailed analysis of individual haplotypes
comprising SNPs involved in the overall test. P-values
were computed by both the method of Shibata et al. and
the CHM (with 500 000 permutations) to investigate the
correspondence between P-values obtained by these two
methods. Haplotype effects were computed by the method
of Shibata et al. (54), as the mean phenotypic values among
individuals carrying one or two copies of the haplotype of
interest.
LD matrices were produced by Haploview version 3.32
(Whitehead Institute for Biomedical Research, USA).
Reverse transcriptase–polymerase chain reaction
RNA samples were purchased from Takara Bio (Palo Alto,
CA, USA; Supplementary Material, Table S3). The cDNAs
were synthesized using 2–5 mg of total RNA with either
cDNA Archive reverse transcription kit (ABI) or Superscript
III reverse transcription kit (Invitrogen, Carlsbad, CA, USA),
using random primer. cDNA samples were amplified using
the GeneAmp XL (rTth DNA polymerase) PCR kit (ABI).
The sequences of the human and mouse primers and amplifi-
cation conditions are listed in the Supplementary Material,
Table S4. The DNA sequence was determined by UNC-CH
Genome Analysis Facility and compared with the predicted
sequence of the 13th exon of the human OPRM1 and human
genomic DNA (UCSC database).
Cloning and expression of the putative IRES element
The C and T allelic variants of putative IRES were cloned into
an NF-kB-SEAP reporter vector (Takara Bio) using unique
HindIII and NruI restriction sites between transcription and
translation start sites of the SEAP reporter (Supplementary
Material, Fig. S6). Human neuroblastoma BE2C cells
(ATCC, Manassas, VA, USA) were grown to 90% confluency
in 12- well plates and transiently transfected using
Lipofectamine-2000 (Invitrogen) with a mixture of either
0.3 mg of pNF-kB-SEAP-IRES(C/T) constructs or original
pNF-kB-SEAP reporter vector and 0.03 mg of pCMC-Luc
(CLONTECH) vector per well. The levels of SEAP mRNA
and enzymatic activity were determined at 8, 24 and 48 h
after transfection, by real-time PCR using SYBRGreen PCR
kit (ABI) and by luminometry using a Great Escape kit
(Takara Bio). Data were normalized for transfection efficiency
by measuring the mRNA levels of Luc for each experimental
point, measured by real-time PCR using SYBRGreen PCR kit
(ABI). Total RNA was isolated using the RNeasy Mini kit
(Qiagen). The isolated RNA was treated with TURBO
DNA-free kit (Ambion, Austin, TX, USA) and reverse tran-
scribed by SuperScript III reverse transcriptase (Invitrogen).
The cDNA for SEAP and Luc was amplified using forward
and reverse PCR primers (AGAGATACGCCCTGGTTCCT
and CCAACACCGGCATAAAGAAT, respectively, for
Luc and GCCGACCACTCCCA-CGTCTT and CCCGCT
CTCGCTCTCGGTAA, respectively, for SEAP). ABI 7900
Real-Time Fluorescence Detection System (ABI) was used
for measuring fluorescence.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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